Welcome to our dedicated page for Senseonics news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics stock.
Senseonics Holdings, Inc. (SENS) is a medical technology company in the surgical and medical instrument manufacturing industry, focused on glucose monitoring products for people with diabetes. Company news frequently centers on its long-term implantable continuous glucose monitoring (CGM) systems, Eversense 365 and Eversense E3, which use an under-the-skin sensor, a smart transmitter, and a mobile app to deliver frequent glucose readings.
News updates for SENS often include financial results and revenue updates, such as preliminary unaudited revenue announcements and quarterly earnings reports. These disclosures provide information on revenue trends, new patient growth, and other operating metrics related to the rollout and adoption of Eversense 365 in the United States and other markets.
Investors and observers can also find corporate and capital markets news, including announcements about a 1-for-20 reverse stock split, special stockholder meetings, and the company’s decision to transfer its stock exchange listing from the NYSE American to the Nasdaq Global Select Market. SEC-related press releases, such as those tied to Form 8-K filings, often accompany these events.
Another key category of Senseonics news involves commercialization and partnership developments. The company has reported on its collaboration with Ascensia Diabetes Care and the planned transition of Eversense 365 commercialization and distribution to Senseonics, as well as its work with Sequel MedTech to integrate the Eversense 365 CGM with the twiist automated insulin delivery system. These updates describe how Eversense technology is being deployed and supported in the diabetes care ecosystem.
Visitors to the SENS news page can review these press releases and related updates to follow Senseonics’ progress in long-term implantable CGM technology, its commercialization strategy for Eversense products, and its ongoing financial and corporate reporting. Regularly checking this page can help readers track how the company’s medical device platform and public company activities evolve over time.
Senseonics Holdings (NYSE: SENS) reported strong early performance indicators for its Eversense 365 launch, which began shipping in November. Key highlights include: doubled Direct-to-Consumer leads in October and November compared to pre-launch months, highest new patient shipments since Ascensia partnership began, 42% increase in prescribing providers, and 69% increase in prescriptions from top prescribers.
The company maintains its target of 50% annual growth in patient installed base for 2024 and reiterates global net revenue guidance of approximately $22 million. One-third of Eversense 365 prescribers are first-time users, and patient switches from competitive CGMs have increased 47% since launch. The company plans a reverse stock split in January 2025 to enhance appeal to institutional investors.
Senseonics Holdings (NYSE American: SENS), a medical technology company specializing in long-term, implantable continuous glucose monitoring systems for diabetes patients, has announced its participation in two upcoming investor conferences in November. The company will present at the Stifel 2024 Healthcare Conference on November 19, delivering a corporate overview and holding one-on-one meetings, with a presentation scheduled for 9:10 am ET. Additionally, management will participate in the Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum on November 21, conducting one-on-one meetings. Both events will be accessible via webcast through the company's investor relations website.
Senseonics Holdings reported Q3 2024 financial results with total revenue of $4.3 million, down from $6.1 million in Q3 2023. The company announced FDA approval for Eversense 365, the world's first 365-day CGM system. Q3 net loss was $24.0 million ($0.04 per share). The company raised over $20 million from equity offerings and implemented restructuring targeting $10M cost reduction in 2025. Full-year 2024 global revenue guidance is approximately $22 million. Cash position stood at $74.8 million with $55.9 million in debt as of September 30, 2024.
Senseonics Holdings (NYSE American: SENS) has announced a $16 million registered direct offering of 45,714,286 common stock shares at $0.35 per share. The company will also issue unregistered warrants to purchase an additional 45,714,286 shares at $0.35 per share in a concurrent private placement. The warrants will be exercisable after six months and expire after five years, potentially generating an additional $16 million if fully exercised. The proceeds will be used for working capital, general corporate purposes, and potentially repaying borrowings on 5.25% Convertible Senior Notes due 2025. The offering is expected to close around October 28, 2024.
Senseonics Holdings (NYSE American: SENS), a medical technology company developing long-term, implantable continuous glucose monitoring systems for diabetes patients, has announced its upcoming third quarter 2024 financial results release. The results will be disclosed after market close on Thursday, November 7, 2024, followed by a conference call at 4:30 p.m. Eastern Time. Investors can access the webcast through the company's website or join via phone using the provided dial-in numbers.
Senseonics Holdings (NYSE American: SENS) announced a virtual KOL event on October 25, 2024, at 11:00am ET to discuss the Eversense® 365 Continuous Glucose Monitoring (CGM) system. This next-generation system, recently cleared by the FDA for people with Type 1 and Type 2 diabetes aged 18 and older, is the world's first one-year CGM system.
The event will feature Dr. David T. Ahn from Hoag Medical Group and Dr. Jeff Ciaramita from Mercy health system, along with company management. They will highlight Eversense 365 in clinical practice and provide an overview of Senseonics' commercial collaboration with Mercy. A live Q&A session will follow the presentations.
Senseonics Holdings, Inc. (NYSE American: SENS) and Mercy healthcare system have announced the first commercial use of the Eversense 365 CGM system, the world's only continuous glucose monitor providing one year of accurate monitoring with minimal interruptions. This milestone marks the beginning of the commercial launch managed by Ascensia Diabetes Care.
Eversense 365, recently approved by the FDA, offers patients with Type 1 and Type 2 diabetes aged 18 and older a differentiated CGM experience, requiring only one sensor replacement per year and one calibration per week. Mercy, serving 3 million patients annually, estimates that about 30,000 of its patients could benefit from this technology.
The long-term monitoring solution aims to improve glycemic control, reduce diabetes-related distress, and lower overall healthcare costs. Senseonics and Mercy expect this breakthrough to enhance the quality of care while reducing costs for providers and payers.
Senseonics Holdings, Inc. (NYSE American: SENS) and Mercy healthcare system have announced the first commercial use of Eversense 365, the world's only 365-day continuous glucose monitoring (CGM) system. This milestone marks the beginning of the commercial launch by Ascensia Diabetes Care for the FDA-approved Eversense 365, which offers patients with Type 1 and Type 2 diabetes a full year of accurate glucose monitoring with minimal interruptions.
Key features of Eversense 365 include:
- One-year monitoring duration
- No additional sensor replacements required
- Only one calibration per week
- Improved glycemic control and reduced diabetes management distress
- Potential to lower overall healthcare costs
Mercy, serving 3 million patients annually, estimates that approximately 30,000 of its patients could benefit from this CGM system. The collaboration between Senseonics and Mercy aims to make this technology accessible to more patients across the U.S.
Ascensia Diabetes Care has launched the Eversense 365 continuous glucose monitoring (CGM) system in the US. Developed by Senseonics Holdings (NYSE American: SENS), it's the world's first and only One Year CGM system, recently cleared by the FDA for people with type 1 and type 2 diabetes aged 18 and older.
Key features of Eversense 365 include:
- One-year accurate monitoring with minimal disruptions
- A tiny sensor that rests under the skin
- Exceptional accuracy over one year
- Reduced diabetes distress and improved glucose control
- Broad commercial insurance coverage
Eligible individuals can pay as little as $199 out of pocket for one year of continuous glucose monitoring through the new Eversense 365 Payment Assistance and Simple Savings (PASS) program.
Senseonics Holdings, Inc. (NYSE American: SENS) and Ascensia Diabetes Care announced FDA clearance for the Eversense 365 CGM system, the world's first one-year continuous glucose monitoring system for people with Type 1 and Type 2 diabetes aged 18 and older. This breakthrough device offers:
- 365-day sensor longevity, reducing frequent sensor changes
- High accuracy and dependability over 12 months
- Removable transmitter for flexibility
- On-body vibration alerts for discretion
Eversense 365 is cleared as an integrated CGM (iCGM) system, compatible with insulin pumps for automated insulin delivery. The U.S. launch is expected in Q4 2024, with Ascensia working to ensure immediate access for users.